Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; …
Over the last 12 months, insiders at Glaukos Corporation have bought $0 and sold $46.72M worth of Glaukos Corporation stock.
On average, over the past 5 years, insiders at Glaukos Corporation have bought $0 and sold $20.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,200 shares for transaction amount of $100,128 was made by Gilliam Joseph E () on 2017‑11‑22.
2024-12-20 | Sale | PRESIDENT & COO | 3,328 0.006% | $149.85 | $498,716 | -1.67% | ||
2024-12-20 | Sale | director | 10,000 0.0181% | $150.28 | $1.5M | -1.67% | ||
2024-12-11 | Sale | director | 2,000 0.0037% | $144.01 | $288,020 | +1.64% | ||
2024-10-30 | Sale | PRESIDENT & COO | 2,275 0.0041% | $138.97 | $316,157 | +1.48% | ||
2024-09-09 | Sale | director | 3,000 0.0055% | $130.67 | $392,000 | +4.87% | ||
2024-08-21 | Sale | PRESIDENT & COO | 5,000 0.0091% | $129.36 | $646,791 | +2.31% | ||
2024-08-15 | Sale | director | 6,250 0.0118% | $125.93 | $787,086 | 0.00% | ||
2024-08-08 | Sale | director | 25,000 0.0453% | $120.00 | $3M | +10.01% | ||
2024-07-05 | Sale | PRESIDENT & COO | 2,250 0.0046% | $121.39 | $273,128 | 0.00% | ||
2024-06-03 | Sale | PRESIDENT & COO | 2,500 0.0049% | $113.50 | $283,751 | +13.07% | ||
2024-05-30 | Sale | director | 5,000 0.01% | $112.00 | $560,000 | +16.27% | ||
2024-05-15 | Sale | director | 6,250 0.0126% | $112.80 | $704,993 | +15.02% | ||
2024-05-10 | Sale | PRESIDENT & COO | 2,395 0.0048% | $110.56 | $264,791 | +15.68% | ||
2024-05-10 | Sale | SVP & CHIEF FINANCIAL OFFICER | 316 0.0006% | $110.43 | $34,896 | +15.68% | ||
2024-05-10 | Sale | SVP & CHIEF FINANCIAL OFFICER | 353 0.0007% | $110.51 | $39,011 | +15.68% | ||
2024-05-06 | Sale | PRESIDENT & COO | 105 0.0002% | $110.36 | $11,588 | +20.85% | ||
2024-05-06 | Sale | SVP & CHIEF FINANCIAL OFFICER | 90 0.0002% | $110.26 | $9,923 | +20.85% | ||
2024-05-02 | Sale | PRESIDENT & COO | 2,059 0.0041% | $105.52 | $217,263 | +20.61% | ||
2024-05-02 | Sale | SVP & CHIEF FINANCIAL OFFICER | 442 0.0009% | $105.69 | $46,713 | +20.61% | ||
2024-04-08 | Sale | PRESIDENT & COO | 59,801 0.1207% | $100.47 | $6.01M | +23.49% |
Gilliam Joseph E | PRESIDENT & COO | 102169 0.1853% | $151.22 | 1 | 40 | +49.43% |
Burns Thomas William | CHAIRMAN & CEO | 55835 0.1013% | $151.22 | 1 | 45 | +18.1% |
WEISNER AIMEE S | director | 30119 0.0546% | $151.22 | 2 | 1 | +57.32% |
MORE ROBERT J | director | 5000 0.0091% | $151.22 | 1 | 0 | |
HARRISON RICHARD L | 1388 0.0025% | $151.22 | 1 | 8 | +18.1% |
BlackRock | $744.61M | 15.68 | 7.9M | +0.03% | +$255,997.35 | 0.02 | |
Fidelity Investments | $693.68M | 14.61 | 7.36M | +26.43% | +$145M | 0.05 | |
The Vanguard Group | $500.58M | 10.54 | 5.31M | +1.38% | +$6.8M | 0.01 | |
Brown Capital Management | $201.11M | 4.24 | 2.13M | -20.94% | -$53.27M | 3.57 | |
State Street | $172.15M | 3.63 | 1.83M | +0.48% | +$829,657.71 | 0.01 |